Oral semaglutide shows promising results for type 2 diabetes in routine clinical settings

FHS
May 28, 2024
1:27 pm

Semaglutide and its effects on glycemic control, body weight (BW), and tolerability in routine clinical practice.

Retinopathy With Long-Term HCQ Use: Large Study IDs Risk Factors

Retinal damage from taking hydroxychloroquine (HCQ) for more than 5 years occurred more frequently among people with certain characteristics, records from nearly 5,000 patients in

May 10, 2024

DFG funds new clinical research unit to study autoimmune-mediated neurological diseases

How do neurological disorders arise that are caused, triggered, or influenced by antibodies? What better possibilities are there for diagnosis – and above all for

July 15, 2023

Zai Lab and Pfizer to commercialise XACDURO in China

XACDURO is the only antimicrobial agent developed to treat carbapenem-resistant Acinetobacter baumannii. Credit: Komsan Loonprom/Shutterstock. Zai Lab and Pfizer have entered a strategic collaboration to

November 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.